Glonghui, December 8 | According to Huaxin Securities Research Report, Dongfulong (300171.SZ) is a leading domestic pharmaceutical equipment leader. Thirty years of industry accumulation have created strong manufacturing technology advantages, and the business has expanded into high-growth emerging fields such as life science, so it is optimistic about future product releases. Maintain a “buy” investment rating. As a pioneer in domestic pharmaceutical equipment going overseas, the company's overseas products are highly complex, there are many systematic orders, and outstanding profitability. In the first half of 2023, the gross margin of the company's overseas business reached 50.5%, achieving overseas revenue of 581 million yuan, with export sales accounting for 19.7% of revenue. As the delivery of the company's overseas products accelerates, its contribution to overseas market performance is expected to increase further, and market development efficiency is expected to continue to be unleashed.